FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a recombinant vector containing a promoter functionally connected to a sequence that encodes a tyrosine kinase B receptor (TrkB) and a sequence that encodes a TrkB receptor agonist; it can be used in medicine.
EFFECT: resulting vector, where the TrkB receptor agonist is a mature brain-derived neurotrophic factor (BDNF) or mature neurotrophin-4 (NT-4), can be effectively used in the treatment, prevention or reduction of the intensity of neurodegenerative disorder.
38 cl, 20 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GENETIC CONSTRUCT | 2016 |
|
RU2734678C2 |
| NON-HUMAN ANIMALS CONTAINING THE HUMANIZED TrkB LOCUS | 2018 |
|
RU2800428C2 |
| HPV-SPECIFIC BINDING MOLECULES | 2018 |
|
RU2804664C2 |
| UNIVERSAL VACCINE BASED ON COMMON TUMOR NEOANTIGENS FOR THE PREVENTION AND TREATMENT OF CANCER WITH MICROSATELLITE INSTABILITY (MSI) | 2018 |
|
RU2792843C2 |
| NEOANTIGENS AND THEIR USE | 2019 |
|
RU2813924C2 |
| ANTIBODIES BINDING CTLA-4 AND APPLICATION THEREOF | 2018 |
|
RU2756100C1 |
| ARTIFICIAL ANTIGEN-PRESENTING CELLS AND METHODS FOR THEIR APPLICATION | 2018 |
|
RU2763798C1 |
| PARTICLES CONJUGATED TO PEPTIDE | 2014 |
|
RU2813163C2 |
| USE OF ANTIBODIES TO SCLEROSTIN FOR TREATING OSTEOGENESIS IMPERFECTA | 2017 |
|
RU2789033C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
